The Rationale for “Laser‐Induced Thermal Therapy (LITT) and Intratumoral Cisplatin” Approach for Cancer Treatment

Abstract

Cisplatin is one of the most widely used anticancer drugs in the treatment of various types of solid human cancers, as well as germ cell tumors, sarcomas, and lymphomas. Strong evidence from research has demonstrated higher efficacy of a combination of cisplatin and derivatives, to-gether with hyperthermia and light, in overcoming drug resistance and improving tumoricidal ef-ficacy. It is well known that the antioncogenic potential of CDDP is markedly enhanced by hyper-thermia compared to drug treatment alone. However, more recently, accelerators of high energy particles, such as synchrotrons, have been used to produce powerful and monochromatizable radiation to induce an Auger electron cascade in cis‐platinum molecules. This is the concept that makes photoactivation of cis‐platinum theoretically possible. Both heat and light increase cisplatin anti-cancer activity via multiple mechanisms, generating DNA lesions by interacting with purine bases in DNA followed by activation of several signal transduction pathways which finally lead to apop-tosis. For the past twenty‐seven years, our group has developed infrared photo‐thermal activation of cisplatin for cancer treatment from bench to bedside. The future development of photoactivatable prodrugs of platinum‐based agents injected intratumorally will increase selectivity, lower toxicity and increase efficacy of this important class of antitumor drugs, particularly when treating tumors accessible to laser‐based fiber‐optic devices, as in head and neck cancer. In this article, the mechanistic rationale of combined intratumor injections of cisplatin and laser‐induced thermal therapy (CDDP–LITT) and the clinical application of such minimally invasive treatment for cancer are re-viewed.